市場調査報告書：血液疾患治療

Abstract

INTRODUCTION

This report details the Market for Blood Disorder Treatments. The market is rapidly growing due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnosis. Emphasis has been placed on early detection and treatment of disorders. There are issues surrounding this market that are currently in the news that will ultimately shape this market for the future. An assessment of this market is presented to ensure that participants in the market do not get caught off guard, not having time to prepare for the future developments.

The objectives of the study are to heighten the awareness of blood disorders, their consequences and their treatments. The study analyzes pharmaceutical entities that are currently on the market and new products that are on the horizon.

SCOPE OF STUDY

This report contains:

Descriptions of various types of blood disorder treatments for anemia, hemophilia, neutropenia and thrombosis
The current market status of blood disorder treatments, trends and forecasts for growth over the next 5 years
Discussion of new technologies with a thorough patent analysis
Analysis of the major overhaul of the U.S. Food and Drug Administration' s approval process for blood disorder treatments
Profiles of major players in the blood disorder treatment market.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC Research report are based on extensive first-hand interviews with primary executives, product managers, and clinical specialists in the area of blood disorders. Background information was obtained from various government, business, medical, and hematology journals and trade magazines, as well as interviews with hematologists, physicians, and nurses involved in hematological conditions. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in the area of blood disorders. Interviews were also conducted to confirm and/or adjust market size and market share estimates, as well as to formulate market projections.

All market data pertain to revenues at the manufacturer' s level. Data are expressed in current U.S. dollars. The base year was 2007. Historical data are provided for 2005 and 2006, and forecast data are provided for 2012. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2007 base year.

Blood Disorder Treatments
Chapter 1 - EXECUTIVE SUMMARY
- EXECUTIVE SUMMARY
- Summary Table: MARKET SIZE OF WORLDWIDE BLOOD DISORDER TREATMENTS BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2012 ($ MILLIONS)
- Summary Figure: MARKET SIZE OF BLOOD DISORDER TREATMENTS BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2005-2012 ($ MILLIONS)
Chapter 2 - INDUSTRY OVERVIEW
- STRUCTURE AND FUNCTION OF THE HEMATOLOGICAL SYSTEM
- BONE MARROW
- BLOOD CELLS
  - Red Blood Cells
  - White Blood Cells
  - Platelets
- SPLEEN
- LYMPH SYSTEM
- LIVER
- NORMAL CLOTTING MECHANISMS
- EFFECTS OF AGING ON THE HEMATOLOGIC SYSTEM
- BLOOD-RELATED MEDICAL CONDITIONS
  - ANEMIA
- Table 1 COMMON CAUSES OF ANEMIA
  - Anemia (Continued)
  - Anemia Caused by Decreased Erythrocyte Production
  - Iron Deficiency Anemia
  - Thalassemia
  - Megaloblastic Anemia
  - Vitamin B12 Deficiency
  - Anemia of Chronic Disease
  - Aplastic Anemia
  - Anemia Caused by Blood Loss
  - Anemia Caused by Increased Erythrocyte Destruction
  - Sickle Cell Disease
  - Glucose-6-Phosphate Dehydrogenase Deficiency
  - Acquired Hemolytic Anemia
  - Polycythemia
- Table 2 TYPES OF ANEMIA
- Table 2 (CONTINUED)
  - HEMOPHILIA
- Table 3 COMMON CAUSES OF HEMOPHILIA
  - NEUTROPENIA
- Table 4 COMMON INFECTIOUS CAUSES OF NEUTROPENIA
- Table 5 COMMON MEDICATION CAUSES OF ANEMIA
  - THROMBOCYTOPENIA
- Table 6 COMMON CAUSES OF THROMBOCYTOPENIA
  - THROMBOSIS
    - Thromboembolus
    - Deep Vein Thrombosis
- Table 7 COMMON CAUSES OF THROMBOSIS
  - DEMOGRAPHICS AND STATISTICS
- Table 8 U.S. CASES OF SELECTED CHRONIC CONDITIONS/ DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007
- Table 8 (CONTINUED)
- Figure 1 U.S. CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%)
- Table 9 WORLDWIDE CASES OF SELECTED CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007
- Figure 2 WORLDWIDE CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%)
- Table 10 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)
- Figure 3 U.S. POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)
- Table 11 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)
- Figure 4 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)
  - LICENSING DISPUTES
    - Licensing Disputes (Continued)
    - Licensing Disputes (Continued)
    - Licensing Disputes (Continued)
  - REBATE ISSUES
  - FDA RESTRICTIONS ON ANEMIA DRUGS
  - TELEMEDICINE FOR HEMOPHILIA
  - HEMOPHILIA AND JOINT DAMAGE
  - EDUCATION
  - COST
  - PHARMACEUTICAL LANDSCAPE CHANGES
    - THE IMPACT OF BIOTECHNOLOGY
      - The Impact of Biotechnology (Continued)
      - The Impact of Biotechnology (Continued)
- Table 12 MARKETED BIOTECHNOLOGY BLOOD TREATMENTS
- Table 12 (CONTINUED)
- Table 13 MARKETED BIOTECHNOLOGY PRODUCT IMPACT
- Table 13 (CONTINUED)
  - BIOGENERIC IMPACT
  - SEDENTARY LIFESTYLES AND DVT
  - MEDICARE AND THE ELDERLY
    - Medicare and the Elderly (Continued)
  - AIRLINE TRAVEL ISSUES
    - Airline Travel Issues (Continued)
  - PHARMACEUTICAL REBATE ISSUES
- PRODUCT SEGMENTS BY TYPE
  - ANEMIA TREATMENTS
    - Aranesp/Nespo (Darbepoetin Alfa)
    - Procrit/Eprex (Epoetin Alfa)
    - Epogen (Epoetin Alfa)
    - NeoRecormon/Epogin (Epoetin Beta)
- Table 14 KEY ANEMIA TREATMENTS
  - Anabolic Steroids
  - Cyanocobalamin and Combinations
  - Erythropoiesis Stimulants
  - Folic Acid and Derivatives
  - Iron and Derivatives
- HEMOPHILIA TREATMENTS
  - Recombinants Group (Baxter)
  - Kogenate
  - NovoSeven
- Table 15 KEY HEMOPHILIA TREATMENTS
  - Antihemophilic Factor
  - Anti-Inhibitor Coagulant Complex
  - Factor IX Complex
- NEUTROPENIA TREATMENTS
  - Neulasta/ Neupopeg (Pegfilgrastim)
  - Neupogen/ Granulokine (Filgrastim)
- Table 16 KEY NEUTROPENIA TREATMENTS
  - Granulocyte Colony Stimulating Factor
  - Granulocyte Macrophage Colony Stimulating Factor
- THROMBOSIS TREATMENTS
  - Lovenox (Enoxaparin Sodium)
  - Plavix (Clopidogrel Bisulfate)
- Table 17 KEY THROMBOSIS TREATMENTS
  - Anticoagulants
  - Antiplatelet Agents
  - Antithrombin III Agents
  - Thrombin Inhibitors
  - Thrombolytic Agents
- NEW APPROVALS
- Table 18 NEWLY APPROVED BLOOD DISORDER TREATMENTS
- Table 18 (CONTINUED)
- Figure 5 PERCENT OF RECENT BLOOD DISORDER APPROVALS BY TREATMENT TYPE (%)
Chapter 3 - MARKET SIZE AND GROWTH
- Table 19 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS, 2005-2012 ($ MILLIONS)
  - BLOOD DISORDER TREATMENT MARKET BY GEOGRAPHY
- Table 20 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 7 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - BLOOD DISORDER TREATMENT MARKETS BY SEGMENT
    - ANEMIA TREATMENTS MARKET
- Table 21 GLOBAL MARKET FOR ANEMIA TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 8 GLOBAL MARKET FOR ANEMIA TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 22 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 9 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - HEMOPHILIA TREATMENTS MARKET
- Table 23 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 10 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 24 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 11 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - NEUTROPENIA TREATMENTS MARKET
- Table 25 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 12 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 26 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 13 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
  - THROMBOSIS TREATMENTS
- Table 27 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, THROUGH 2012 ($ MILLIONS)
- Figure 14 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, 2005-2012 ($ MILLIONS)
- Table 28 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)
- Figure 15 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, 2005-2012 ($ MILLIONS)
Chapter 4 - RESEARCH AND DEVELOPMENT
- Table 29 SELECTED BLOOD DISORDER TREATMENTS IN DEVELOPMENT
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
- Table 29 (CONTINUED)
  - TREATMENTS AWAITING APPROVAL/PHASE TRIALS
    - AWAITING APPROVAL
      - Angiomax/Angiox
      - Hemopure
      - Mircera/C.E.R.A./R744
      - EPOCH
      - Ferinject
      - Lovenox
      - Plavix
      - Soluble Ferric Pyrophosphate (SFP)
    - PHASE III CLINICAL TRIALS
      - AMG-531
      - Apixaban
      - ATryn
      - AZD-6140
      - Beriplex P/N
      - Idraparinux Long-Acting Pentasaccharide
      - Cangrelor
      - Elaprin
      - Ferumoxytol
      - Hematide
      - Hemospan
      - Hemoxin/Nicosan/Niprisan
      - ICA-17043
      - Mozobil (AMD3100)
      - NovoSeven
      - Oxygent
      - PolyHeme
      - Procrit (Epoetin Alfa)
      - Promacta (Eltrombopag Olamine)
      - Refacto AF
      - Rendix (Dabigatran Etexilate)
      - Rivaroxaban (BAY 59-7939)
Chapter 5 - INDUSTRY STRUCTURE
- COMPETITIVE ANALYSIS
- Table 30 TOTAL MANUFACTURERS' MARKET SHARES OF BLOOD DISORDER TREATMENTS, 2007
- Table 30 (CONTINUED)
- Figure 17 TOTAL MANUFACTURERS' MARKET SHARES OF BLOOD DISORDER TREATMENTS, 2007
  - ANEMIA TREATMENTS
- Table 31 TOTAL MANUFACTURERS' MARKET SHARES OF ANEMIA TREATMENTS, 2007
- Figure 18 TOTAL MANUFACTURERS' MARKET SHARES OF ANEMIA TREATMENTS, 2007 (%)
  - HEMOPHILIA TREATMENTS
- Table 32 TOTAL MANUFACTURERS' MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007
- Figure 19 TOTAL MANUFACTURERS' MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007 (%)
  - NEUTROPENIA TREATMENTS
- Table 33 TOTAL MANUFACTURERS' MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007
- Figure 20 TOTAL MANUFACTURERS' MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007 (%)
  - THROMBOSIS TREATMENTS
- Table 34 TOTAL MANUFACTURERS' MARKET SHARES OF THROMBOSIS TREATMENTS, 2007
- Figure 21 TOTAL MANUFACTURERS' MARKET SHARES OF THROMBOSIS TREATMENTS, 2007
  - INDUSTRY PARTICIPANTS BY PRODUCT TYPE
- Table 35 BLOOD DISORDER TREATMENT MANUFACTURERS BY PRODUCT TYPE, 2007
- Figure 22 BLOOD DISORDER TREATMENT MARKETS-NUMBER OF KEY MANUFACTURERS BY PRODUCT TYPE, 2007 (%)
Chapter 6 - PATENTS
- PATENT ANALYSIS BY MANUFACTURER
- Table 36 SELECTED MANUFACTURER PATENTS FOR BLOOD DISORDER AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
  - PATENTS BY APPLICATION
    - Anemia Applications
    - Hemophilia
    - Neutropenia
    - Thrombosis
  - LEADING MARKET MANUFACTURERS
- Table 37 PATENT ANALYSIS BY SELECTED LEADING BLOOD DISORDER TREATMENT MANUFACTURERS, 1976-PRESENT
Chapter 7 - COMPANY PROFILES
- AMGEN, INC.
- BAXTER INTL., INC.
- BAYER AG
- BIOPURE CORPORATION
- BRISTOL-MYERS SQUIBB CO.
- CHUGAI PHARMACEUTICAL CO., LTD.
- CSL BEHRING
- GENZYME
- TEL: 617/252-7500
- GLAXOSMITHKLINE, PLC
- ICAGEN, INC.
- MEDICINES COMPANY (THE)
- NOVO NORDISK A/S
- ORTHO BIOTECH PRODUCTS, LP
- ROCHE
- SANOFI-AVENTIS
- SCHERING-PLOUGH CORP.
- WYETH
Chapter 8 - APPENDICES
- COMPANY CONTACT INFORMATION
- Table 38 LIST OF COMPANIES
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
- Table 38 (CONTINUED)
  - BLOOD DISORDER ASSOCIATIONS AND RESOURCES CONTACT INFORMATION
    - BLOOD DISORDER ASSOCIATIONS (CONTINUED)
    - BLOOD DISORDER ASSOCIATIONS (CONTINUED)

血液疾患治療

Blood Disorder Treatments

Abstract

INTRODUCTION

SCOPE OF STUDY

METHODOLOGY AND INFORMATION SOURCES

Table of Contents